Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04590326
Title Study of REGN5668 Administered in Combination With Cemiplimab or REGN4018 in Adult Women With Recurrent Ovarian Cancer.
Recruitment Recruiting
Gender female
Phase Phase Ib/II
Variant Requirements No
Sponsors Regeneron Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | BEL

Facility Status City State Zip Country Details
City of Hope RECRUITING Duarte California 91010 United States Details
H. Lee Moffitt Cancer Center RECRUITING Tampa Florida 33612 United States Details
Northwestern Memorial Hospital RECRUITING Chicago Illinois 60611 United States Details
University of Chicago RECRUITING Chicago Illinois 60637 United States Details
Massachusetts General Hospital Cancer Center RECRUITING Boston Massachusetts 02114 United States Details
Dana Farber Cancer Institute RECRUITING Boston Massachusetts 02215 United States Details
Karmanos Cancer Institute RECRUITING Detroit Michigan 48201 United States Details
Memorial Sloan Kettering Cancer Center RECRUITING New York New York 10065 United States Details
The Ohio State University Wexner Medical Center RECRUITING Columbus Ohio 43210 United States Details
University of Pennsylvania RECRUITING Philadelphia Pennsylvania 19104 United States Details
Seattle Cancer Care Alliance RECRUITING Seattle Washington 98109 United States Details
Universitair Ziekenhuis Leuven RECRUITING Leuven Vlaams-Brabant 3000 Belgium Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field